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Abstract
Background: Benign primary bone tumors are commonly treated by surgery involving bone grafts or synthetic
bone void fillers. Although synthetic bone grafts may provide early mechanical support while minimizing the risk of
donor-site morbidity and disease transmission, difficult handling properties and less than optimal transformation to
bone have limited their use.
Methods: In a prospective series, patients with benign bone tumors were treated by minimal invasive intervention
with a bi-phasic and injectable ceramic bone substitute (CERAMENT™ BONE VOID FILLER, BoneSupport, Sweden)
with the hypothesis that open surgery with bone grafting might be avoided. The defects were treated by either
mini-invasive surgery (solid tumors) or percutaneous injection (cysts) and followed clinically and radiologically for
12 months. CT scan was performed after 12 months to confirm bone remodeling of the bone substitute. All
patients were allowed full weight bearing immediately after surgery.
Results: Fourteen patients with a median age of 13 years (range 7–75) were consecutively recruited during
11 months. Eleven lesions were bone cysts (eight unicameral and three post-traumatic) and three were solid
benign tumors. The median size of the lesions was 40 mL (range 1–152). The most common location was
humerus (n = 10). After 12 months the defects completely or partially filled with median 18 mL (range 5–28)
of bone substitute demonstrated full resolution (Neer Classification grade I) in 11 patients, partial resolution
(Neer II) in 2 patients and in 1 patient the cyst persisted (Neer III).
No lesions required recurrent surgery during the observation period. No post-operative fracture or infection
was recorded.
Conclusions: Minimal invasive treatment with a bi-phasic and injectable ceramic bone substitute might offer
an alternative to regular bone grafting due to convenient handling properties and rapid bone remodeling.
Trial Registration: ClinicalTrials NCT02567084 Release Date 10/01/2015
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Background
Benign bone tumors are often treated with intrale-
sional curettage which creates a bone defect that can
be filled with e.g. demineralized bone matrix, autolo-
gous bone, ceramic bone substitutes or polymethylme-
tacrylate cement [1–4].
Autograft has been considered the golden standard
because it possesses all three of the essential elements
required for an optimal bone graft [5], but is associ-
ated with morbidity at the donor site and is limited in
supply [6]. Allograft has been employed as a good al-
ternative to autograft but the concern for potential
disease transmission remains [7]. Synthetic bone graft
substitutes have been gaining popularity as viable al-
ternatives for void and defect filling eliminating the
concerns with autograft and allograft. These synthetic
bone substitutes have invariably been based on calcium
phosphate and/or calcium sulfate materials which are
osteoconductive and facilitate bone remodeling, al-
though either side effects such as drainage and wound
complications [8, 9] slow remodeling to bone [10, 11] or
negligible bone generation [9, 12] have limited their use.
Thus, new synthetic bone substitutes with described posi-
tive effects in vertebroplasty [13, 14], osteotomy [15], and
smaller trauma defects [16] merit further investigation
also in treatment of larger bone defects.
Presented here are the 12 months radiological and
functional results of a prospective patient series of be-
nign bone tumors treated with a rapidly remodeling bi-
phasic injectable ceramic bone substitute [17] applied
either percutaneously or through mini-invasive surgery,
with the hypothesis that open surgery and bone grafting
might be avoided with acceptable clinical outcome.
Methods
Materials
A bi-phasic ceramic bone substitute (CERAMENT™
BONE VOID FILLER, Bone Support AB, Lund, Sweden)
composed of 60 % weight synthetic calcium sulfate
(CaS) and 40 % weight hydroxyapatite (HA) powder was
mixed with a water-soluble radio-contrast agent iohexol
(180 mg/ml) to make the material radiopaque. The com-
bination produces an easily injectable paste that sets
within 15 min and fully hardens after 60 min and shows
a wet compressive strength exceeding that of healthy
cancellous bone [18]. The CaS component undergoes
gradual reabsorption during the first months being re-
placed by in-growing bone that remodels to form tra-
becular bone whereas the HA component has a slower
reabsorbing rate and is incorporated into the newly
formed trabecular bone [17].
Patient handling
Fourteen consecutive patients fulfilling the criteria of
having a benign bone lesion requiring bone grafting after
surgery were included. Exclusion criteria were known
hyperthyroidism or autonomous thyroid adenoma, his-
tory of serious reaction to iodine based radio-contrast
agents, local infection at the site of implantation, pre-
existing calcium metabolism disorder (e.g. hypercalce-
mia), or a bleeding disorder.
The volume of defects was calculated on plain radio-
grams as: width/2 × depth/2 × height × π for defects of
cylindrical form and width/2 × depth/2 × height/2 × 4/3π
for spherical defects [19].
Bone cysts of a volume exceeding 100 cc were treated
with an injection of 1–2 mL of methyl prednisolone
40 mg/mL (Depot Medrol®, Pfizer) in an attempt to in-
duce bone generation and reduce the cyst volume. When
further reduction of the cyst volume was needed, 1 or 2
repeated injections were performed at an interval of
6 months [20].
Due to our lack of experience in injecting the actual
product at volumes bigger than 30 cc, and after con-
sultation with the manufacturer, this amount was set
as the maximum treatment volume in spite of some
defects being bigger. All patients were assessed pre-
Fig. 1 Two needles technique. Transcortical administration of the flowable bone substitute by the use of one injection needle and one
“ventilation” needle. Before (left) and immediately after (right) injection of the bone substitute
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operatively to calculate the volume of the defect and
to decide whether the entire defect could be filled
with the bone substitute or if critical parts of the de-
fect should be prioritized. Critical parts were defined
as regions within the defect considered by the sur-
geon to be at highest risk for fracture. Full weight
bearing was allowed immediately after surgery. All
patients underwent radiographic examination with X-
ray pre-operatively, post-operatively and after 3 and
12 months, and 11 patients underwent CT scan after
12 months to investigate possible bone bridging of
the defect. All patients were giving their informed consent
written and the study was approved by Ethics Committee
of Medical University im. Karola Marcinkowskiego in
Poznan Collegium Maiusul. Fredry 10 61–701 Poznań
Local Ethics Committee. The research reported in the
paper was undertaken in compliance with the Helsinki
Declaration.
Surgical technique
All procedures were performed under general anesthesia
guided by fluoroscopy. To minimize the risk of soft tis-
sue leakage a mini-invasive technique was used. Solid
benign tumors were removed through a cortical bone
window big enough to allow biopsies for histopatho-
logical examination and to ensure radical excision. For
bone cysts a completely closed technique was used. An
11 gauge bone needle was introduced transcortically
under fluoroscopy into the proximal part of the cyst to
act as a ventilation needle, and another needle was simi-
larly placed at the distal end (Fig. 1). Such a two-needle-
system provides more control and efficiency in cyst
filling or aspiration due to low injection or aspiration
pressure. The cyst fluid was then aspirated followed by
repeated flushing with 0.9 % saline. In the case of single
bone membranes the needle was forced through the
bone to ensure best possible communication. To enable
bone remodeling of the subsequently injected bone substi-
tute proper contact with cancellous bone was ensured by
spot-wise scratching of the epithelial lining with the tip of
the needle until bleeding was demonstrated in the saline.
The bone substitute paste was then prepared by mix-
ing the liquid component containing iohexol with the
Fig. 2 Transcortical injection. The bone graft material injected
through an 11G bone needle into a calcaneal bone cyst under
fluoroscopic guidance. Note the high radiovisibility caused by the
addition of water-soluble radio-contrast agent
Table 1 Modified Neer classification of radiologic results
Score Classification Description Treatment
I Healed Cyst filled with new bone,
with or without small
radiolucent area(s)





< 50 % of the diameter
of the bone with enough
cortical thickness to prevent
fracture
Not necessary
III Persistent cyst Radiolucent area > 50 %
of the diameter of the
bone and with a thin
cortical rim; no increase








Cyst reappeared in a
previously obliterated area




Table 2 Details of patients
No. Symptom Location Diagnosis Size (cm3)
1 Pain Finger Enchondroma 1
2 Pain Humerus UBC 62
3 Fracture Humerus Post-traumatic 152
4 Pain Humerus UBC 24
5 Pain Humerus Chondroblastoma 114
6 Pain Femur Fibrous defect 23
7 Pain Calcaneus UBC 49
8 Pain Humerus UBC 70
9 Pain Humerus UBC 37
10 Fracture Humerus Post-traumatic 38
11 Fracture Humerus Post-traumatic 42
12 Pain Humerus UBC 46
13 Pain Humerus UBC 34
14 Pain Fibula UBC 16
Patient demographics and description of the bone lesions
UBC Unicameral Bone Cyst
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powder for 30 s. At time = 4 min. from the start of
mixing the paste was sufficiently viscous to withstand
dissolution by the rinse fluid and injection was started
through the distal needle with the opposite needle
allowing passive evacuation of the fluid. Due to high
content of iohexol the entire injection could be easily
followed under fluoroscopy (Fig. 2). Although the aim
was to completely fill the cyst, this was far from al-
ways possible due to interfering bone membranes and
excessive cyst volume. After completed filling, stylets
were introduced into the needles and left untouched
until time = 7 min. When resistance was felt at slight
pulling of the needle the two needles were removed
by a rotating movement.
Bone healing was independently evaluated using the
modified Neer score system [1] by an external phys-
ician being a specialist in orthopedic radiology. The
classification is shown in Table 1. CT scan was used
in a qualitative way to demonstrate bone bridging of
the defects and absence of remaining bone substitute,
as an indirect sign of bone remodeling. All patients
received standard post-operative treatment with para-
cetamol 1 g 4 times daily.
Results
Fourteen patients were consecutively recruited at one
center during 11 months and followed for 12 months
without any drop-out. The median age was 13 years with
a range between 7 and 75 years. Eight patients were 14
or younger. Eight lesions were unicameral, three were
post-traumatic bone cysts and other three patients had a
solid benign lesion. The most common lesion location
was the humerus (n = 10). The median volume of the
lesions was 40 mL (range 1–152). The individual demo-
graphic data and description of the bone lesions are
shown in Table 2.
Two patients were treated with repeated injections
of methyl prednisolone (patient 3 and 5) with marginal
effect. The median volume of bone substitute used
was 18 mL (range 5–28). Postoperative drainage lasted
for 1 day (range 1–5). After 12 months full cyst reso-
lution (Neer Classification grade I) was seen in 11 pa-
tients (Figs. 3 and 4) despite incomplete filling (Fig. 5)
in majority of cases (Table 3). Partial healing (Neer II)
was demonstrated in 2 patients and in one patient the
cyst persisted (Neer III). A CT scan after 12 months
confirmed the complete radiological transformation of
a b c
Fig. 3 Full remodeling after 12 months. Patient treated with 15 mL of bone substitute. Pre-op (a), post-op (b) and 12 months follow-up (c)
a b c d e
Fig. 4 Full remodeling after 12 months. Patient with a unicameral bone cyst mini-invasively injected with the synthetic none substitute. Immediately
postop (a, b), at 3 months (c), and after 12 months (d, e)
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the bone substitute into bone (Fig. 6). No post-
operative infections or fractures were recorded during
the 12 months follow-up period. All patients were free
from pain within 10 days, and none required extra
pain medication or treatment with non-steroid anti-
inflammatory drugs.
Discussion
The presented prospective patient series shows a new
bone remodeling technique that relies on the properties
ascribed to the ceramic bone substitute composite used
[17]. The immediate pain relief, full weight-bearing re-
covery, bone consolidation and incorporation as well as
the structural bone integrity and durability demonstrated
in the study indicate that the material can provide a safe
and effective long-term solution for the treatment of be-
nign bone tumors. Of special interest is the ability of
percutaneous transcortical injection under fluoroscopy
in patients with juvenile cysts, which is enabled by mix-
ing the ceramic powder composition with the water sol-
uble radiocontrast agent iohexol.
An interesting observation was that the epithelium of
unicameral cysts did not require complete removal since
multiple scratching with the needle tip was sufficient to
allow fresh bone to come in contact with the ceramic
implant and provide full remodeling to bone. Another
observation was that in spite of incomplete filling
complete or almost complete healing was attained,
which indicates that the material or the procedure trig-
gers a bone healing process beyond that facilitated by
the material itself [19].
The biphasic ceramic bone substitute is designed to
remodel in tune with the natural bone remodeling
process. Due to the microporosity of the cured calcium
sulfate component an immediate flow of tissue fluids
with nutrients and growth factors is allowed so to pene-
trate the implant. That in turn promotes osteoclasts
and macrophages to enter the material and create
macropores resulting in a widespread ingrowth of early
bone [17]. The end result seems to be full transform-
ation and remodeling into mature bone after 9–12
months [13, 15, 17]. In a previous study on a composite
bone graft substitute similarly consisting of calcium sul-
fate and hydroxyapatite (Schindler et al.) the graft ma-
terial was still present after two years, whereas in the
current study a CT-confirmed complete bone remodel-
ing was demonstrated on X-ray after one year in all but
one patient. One explanation for the faster remodeling
a c db
Fig. 5 Full remodeling in spite of incomplete filling. Patient mini-invasively treated with 18 mL of the injectable bone substitute; Pre-op (a). In
spite of incomplete filling (b) a general bone formation process is triggered, which can be seen at 3 months (c) and with complete radiological
remodeling at 12 months (d)
Table 3 Treatment outcome
Patient No. 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Size (cm3) 1 62 152 24 114 23 49 70 37 38 42 46 34 16
CERAMENT™ injected (mL) 1 18 18 15 18 28 23 18 18 10 8 18 18 10
Bone healing (Neer classification) I I II I I I II III I I I I I I
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in the present study might be a more favorable pro-
portion of calcium sulfate to hydroxyapatite (CaS/
HA = 60 to 40 %) compared to that used in the study
by Schindler and co-workers [21] where the graft ma-
terial consisted of somewhat inverted proportion of
35 to 65 %. Reasonably fast remodeling has also been
described with composite calcium phosphate based
products [11, 22].
It has been reported that products consisting of pure
calcium sulfate have a tendency to quickly dissolve
[12] which, together with a low pH [23], leads to a
high frequency of long term drainage [8] and subse-
quent wound complications [9]. Also, products mainly
based on calcium phosphate cements have been re-
ported to cause adverse and sometimes painful soft
tissue reactions [24, 25]. The product used in the
study presents with a neutral pH [17] and once im-
planted a passive precipitation of endogenous hy-
droxyapatite takes places on the implant surface [26],
which seems to extend the gradual resorption of the
calcium sulfate component over months [13] allowing
the cement to resist immediate dissolution and be ac-
tively degraded and replaced by ingrowing bone that
eventually remodels to form trabeculae [18, 27]. These
two product differences (pH and composition) might
partly explain: 1) the absence of prolonged post-
operative drainage and/or late wound complications,
2) the rapid and reliable remodeling to bone [15]. The
minimal invasive technique might also have contrib-
uted to the absence of adverse reactions due to less
leakage into the soft tissue. Although the actual pro-
spective study presents with favorable results, it must
be emphasized that it is a rather small and non-
controlled study which requires repeated and larger
trials to confirm the findings.
Conclusions
The investigated bi-phasic bone substitute seems to be a
material with attractive handling properties including re-
liable injectability, enhanced radio-opacity and fast re-
modeling to bone, which might make it an attractive
alternative to autologous bone or allografts.
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